CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
SuperSaturated Oxygen (SS02) Therapydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01630707
NCT01630707N/ACompleted

MultiCenter Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy in Patients With Anterior Acute Myocardial Infarction ≤ Six Hours After Symptom Onset and Successful Reperfusion (Via PCI)

TherOx·interventional·Posted Jun 28, 2012·Updated May 22, 2026

In Brief

A clinical study evaluating SuperSaturated Oxygen (SS02) Therapy for Anterior Wall Acute Myocardial Infarction. Completed, enrolled 20 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA). The therapy will be delivered with a commercially available qualified SSO2 delivery catheter used with the TherOx® DownStream® System and Cartridge in the treatment of patients presenting with an anterior acute myocardial infarction (heart attack) ≤ six hours after symptom onset with successful reperfusion (via PCI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 28, 2012
Enrollment StartAug 1, 2012
Primary CompletionSep 1, 2013
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.0 years ago

Interventions

SuperSaturated Oxygen (SS02) Therapydevice

Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter